AI-generated summary
The authors report a randomized, double-blind, sham device-controlled trial of home-based 830-nm LED photobiomodulation for thyroidectomy scars, with treatment starting one week after surgery. Among 43 completers, the treatment group reported higher satisfaction and Global Assessment Scale scores and lower pain and Vancouver Scar Scale scores than the sham group at 6 months, while other 3D imaging differences were not significant.
- Participants
- 43
- Who or what was studied
- Patients undergoing thyroidectomy (43 completers: 21 treatment, 22 sham control)
- Wavelengths
- 830 nm
- Limits stated in the abstract
- The abstract reports a small sample of 43 completers and non-significant imaging differences, so the findings are preliminary.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Photobiomodulation, Photobiomodulation therapy, Sham device, Sham, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.